Ashley Ward, APRN
Nurse Practitioner · Stillwater, OKNPI 1780099614
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 588 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $2,736 and has fallen 99.4% since, to $18 in 2025. Among nurse practitioner clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 588 payments — averaging $14.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novartis$1K
- Acadia Pharmaceuticals Inc$797
- SK Life Science, Inc.$589
- UCB, Inc.$413
- AstraZeneca$408
- plus $4K from 39 others
What the payments were for
- Speaking & faculty fees$190%
- Food & beverage$8,699100%
- Education$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$8,737 in reported general payments places this provider in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 21 | $370,730 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 27 | $187,375 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 13 | $138,408 |
| IngrezzaValbenazine Tosylate | 11 | $84,153 |
| NuplazidPimavanserin Tartrate | 13 | $63,636 |
| Nurtec OdtRimegepant Sulfate | 42 | $58,503 |
| Emgality PenGalcanezumab-Gnlm | 75 | $56,512 |
| QuliptaAtogepant | 24 | $26,977 |
| RytaryCarbidopa/Levodopa | 13 | $26,608 |
| EliquisApixaban | 20 | $11,388 |
| Memantine Hcl | 324 | $10,307 |
| Ajovy SyringeFremanezumab-Vfrm | 13 | $9,214 |
| UbrelvyUbrogepant | 11 | $8,836 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,809 |
| Dimethyl Fumarate | 18 | $6,596 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $277 | $84,15311 claims |
| PfizerNurtec Odt, Eliquis | $223 | $69,89162 claims |
| Acadia Pharmaceuticals IncNuplazid | $797 | $63,63613 claims |
| AbbVieQulipta, Ubrelvy, Namzaric | $1,313 | $42,34946 claims |
| Amneal Pharmaceuticals LLCRytary, Mycophenolate Mofetil | $158 | $26,98024 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 824 nurse practitioner providers in Oklahoma.
Other nurse practitioner in Stillwater
- Mirabel FortehStillwater$7K
- Jenny GuthrieTulsa$106K
- Leah MeltonNorman$87K
- Sara GoreOklahoma City$52K
- Teisha GalleglyMoore$43K
- Stacy NewberryTulsa$28K
- Russell RoomsOklahoma City$24K
- Grant YoungOklahoma City$15K
- Monica LawsonNorman$15K
- Amanda SmallTulsa$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.